

Why we should do more Pragmatic Trials and how PRECIS-2 could help

Kirsty Loudon

Impact Fellow

NMAHP Research Unit

E-mail: Kirsty.loudon@stir.ac.uk

Twitter: @KirstyLoudon @PRECIS_2

Skype: Kirsty3



Improving health through research  CHIEF SCIENTIST OFFICE



Aims for today

- Why are Pragmatic trials & PRECIS-2 important?
- PRECIS-2 tool
- Testing PRECIS-2 at the PCTU
- Using PRECIS-2 in 2 pilot studies
- Key design challenges discussed with users
- Conclusions

EXPLANATORY AND PRAGMATIC ATTITUDES IN THERAPEUTICAL TRIALS

DANIEL SCHWARTZ and JOSEPH LELLOUCH

Unité de Recherches Statistiques, Institut National de la Santé et de la Recherche Médicale,
94 Villejuif, France

(Received 6 January 1967; in revised form 24 March 1967)

It is the thesis of this paper that most trials are inadequately formulated. Their inadequacy is basic, in that trials may be aimed at the solution of one or other radically different kinds of problems.

Most trials done hitherto have adopted the explanatory approach without question; the pragmatic approach would often have been more justifiable.

J. chron. Dis. 1967, Vol. 20, pp. 637–648. Pergamon Press Ltd.

Why is it important?

- **Pragmatic trials** – Trials that test if an intervention will work in *usual* conditions
- **Explanatory trials** – Trials that test if an intervention will work in highly controlled, *ideal* circumstances
- **Continuum** *not* Dichotomy

[Explanatory and pragmatic attitudes in therapeutical trials \(1967\).](#)

Schwartz D, Lellouch J. Republished in J Clin Epidemiol. 2009;62(5):499-505

71% of RCTs do not represent real world patients

Kennedy-Martin *et al. Trials* (2015) 16:495
DOI 10.1186/s13063-015-1023-4



REVIEW

Open Access




A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

Tessa Kennedy-Martin^{1*}, Sarah Curtis², Douglas Faries², Susan Robinson¹ and Joseph Johnston²

Abstract

Randomized controlled trials (RCTs) are conducted under idealized and rigorously controlled conditions that may compromise their external validity. A literature review was conducted of published English language articles that reported the findings of studies assessing external validity by a comparison of the patient sample included in RCTs reporting on pharmaceutical interventions with patients from everyday clinical practice. The review focused on

PRECIS-2 wheel



PRECIS-2 key feature

Improve *applicability* of trial results


HELP trialists think about *consequences* of *design decisions*

So trialists consider “*how different is the trial.... to usual care*”

Organisation domain in PRECIS-2

- How **different** are the **resources, provider expertise and the organisation of care delivery** in the intervention arm of the trial and those available in **usual care**?
- For example, score **5** for very pragmatic choice with identical organisation to usual care;
- score **1** for a very explanatory approaches if the trial increases staff levels, gives additional training, requires more than usual experience or certification and increase resources.

Pragmatic Clinical Trials Unit trials



Forbes G. Understanding the applicability of results from primary care trials: lessons learned from applying PRECIS-2 J Clin Epi 2017G

Using PRECIS-2 to discuss the design of a feasibility study: SiP

A Swallowing intervention Package (SiP)


Methods

- 14 trial team members
- 11 PRECIS-2 wheels independently created pre-meeting
- Meeting to discuss results

Results

- Greater consensus following meeting
- Useful tool to frame the conversation around discussing trial design
- Useful tool to assess pilot study and future RCT
- Fun

SiP feasibility study



Useful to assess feasibility study and future RCT

Process Evaluation in Pilot Study

- Ease and suitability of the PRECIS-2 tool to be used as an assessment tool during the process and implementation evaluation.
- Pre-intervention
- During intervention
- Post-intervention

Pragmatic trial assessment


RESEARCH

Open Access



Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory

Karin E. Johnson^{1†}, Gila Neta^{2*†}, Laura M. Dember³, Gloria D. Coronado⁴, Jerry Suls², David A. Chambers², Sean Rundell⁵, David H. Smith⁴, Benmei Liu², Stephen Taplin², Catherine M. Stoney⁶, Margaret M. Farrell² and Russell E. Glasgow⁷



--- Planning phase
— Implementation phase

Few challenges of Pragmatic trials

- Usual care including outside NHS
- Blinding
- Recruitment and informed consent
- Working with collaborators
- Organisation limitations

PRECIS-2 website

Top 10 Countries

1.  United States
2.  United Kingdom
3.  Canada
4.  Spain
5.  Australia
6.  Japan
7.  Norway
8.  Netherlands
9.  New Zealand
10.  Austria

Registered users

363 entries

Number of wheels

309 entries



PRECIS-2

Designing clinical trials is challenging. PRECIS - PRagmatic EXplanatory Continuum Indicator Summary - is a clever acronym for a tool to help trialists designing clinical trials consider where they would like their trial to be on the pragmatic/explanatory continuum.


The PRECIS-2 website has two functions

1. a training resource;
2. a database of trials that have been scored using PRECIS-2

Trialists working on their own trial can [apply for a password](#) so that their team can score their trial while developing the trial design and protocol. This trial design information will *only* be visible to trialists using a password until they decide to make this information publically available. We advise one password per trial team so you all have access to score the same trial. A PRECIS-2 wheel will be generated, based on all the scores, and can be used for discussion and consensus.

The database of trials contains trials that are a spectrum of pragmatic trials. We hope this will be helpful to researchers who can then search for trials on particular topics and consider the trial design. In addition trialists can look at the internal validity using the Risk of Bias tool©.

Figure: The PRagmatic-Explanatory Continuum Indicator Summary 2 (PRECIS-2) wheel.
Adapted from *BMJ* 2015;350:h2147



www.PRECIS-2.org

Summary & Conclusions

- PRAGMATIC trials test interventions in routine practice
- PRECIS-2: An efficient way to DESIGN more pragmatic trials that are more likely to meet the needs of patients, health care professionals
- Increases TRANSPARENCY in design decision making and helps guide the conversation about design from pilot to full RCTs.

Useful References and Websites

PRECIS-2 Website: www.PRECIS-2.org

Users' Guide to Pragmatic Trials <http://crispebooks.org/PragmaticTrialsEbook>

NIH Collaboratory Rethinking Clinical Trials <http://www.rethinkingclinicaltrials.org/>

Implementation Science Website: <http://dccps.cancer.gov/is/>

Loudon K. Treweek S, Sullivan P, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: Designing trials that are fit for purpose. *BMJ* 2015;350:h2147.

Johnson KE et al, Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory. *Trials* 2016; 17:32

Forbes G, Loudon K et al. Understanding the applicability of results from primary care trials: lessons learned from applying PRECIS-2 *J Clin Epi* 2017

Zwarenstein M, Loudon K... Understanding pragmatism and PRECIS-2 *J Clin Epi* 2017

To be *pragmatic* or not to be, that is the question...

“A pragmatic approach to pragmatism would be to adopt the features of pragmatic trials whenever feasible and sensible and when such features do not compromise trial quality and the ability to answer the clinical question of interest.”

Ford & Norrie Pragmatic Trials. NEJM 2016;375:454-63.

Thank you for listening!



Any questions?

Kirsty kirsty.loudon@stir.ac.uk

Twitter: [@PRECIS_2](https://twitter.com/PRECIS_2) [@KirstyLoudon](https://twitter.com/KirstyLoudon)